8 July 2013 – Parsortix trial
Successful results from a trial carried out by the University of Surrey Oncology Group have confirmed that the Parsortix system has been performing well. This is further validation of the technology and will move the company closer to the point when it can generate meaningful revenues and profits. We maintain our recommendation of BUY.